Annals of Oncology 6:589-594, 1995
© 1995 European Society for Medical Oncology
research-article |
Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53
Istituto di Ricerche Farmacologiche ‘Mario Negri’ Milan, Italy
Correspondence to: Dr. Massimo Broggini, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via Eritrea 62 20157 Milan, Italy
BACKGROUND: The cytotoxicity and gene expression induced by anticancer drugs with different mechanisms of action was tested in clones from a human ovarian cancer cell line expressing no p53, mutated p53 or wild type (wt) p53.
MATERIALS AND METHODS: We used clones from SKOV3 cells transfected with a temperature-sensitive mutant p53 which expresses mutated p53 at 37 °C and a wild type-like p53 at 32 °C. Cytotoxicity and expression of p53-related genes (WAF1 and GADD45) were tested after 24 hours of treatment with different drugs.
RESULTS: All of the drugs were equally active in the different systems, independently of the presence of p53, with the exception of doxorubicin which was less cytotoxic in cells expressing a wtp53. An increase in the transcription of WAF1 and GADD45 genes was found in cells expressing p53 and treated with the drugs. GADD45 and WAF1 expression was also found in cells not expressing p53 but treated with the drugs, suggesting that these genes can also be activated by DNA damage through a pathway independent of p53. A highly DNA-sequence-specific alkylator, tallimus-tine (FCE 24517), which causes a very small number of DNA lesions, does not increase the expression of these genes. Cyclin Dl gene expression was not changed after treatment with the drugs tested in cells both expressing and not expressing wtp53.
CONCLUSIONS: Our data suggest that p53 expression does not play a role in increasing the susceptibility of cells not undergoing apoptosis after DNA damage, but that, at least in the case of doxorubicin, it can enhance the repair systems and reduce the cytotoxicity.
p53 expression, anticancer agents, p53-related genes, p53 binding
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. A. Goyeneche, R. W. Caron, and C. M. Telleria Mifepristone Inhibits Ovarian Cancer Cell Growth In vitro and In vivo Clin. Cancer Res., June 1, 2007; 13(11): 3370 - 3379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Vikhanskaya, M. M. Siddique, M. Kei Lee, M. Broggini, and K. Sabapathy Evaluation of the Combined Effect of p53 Codon 72 Polymorphism and Hotspot Mutations in Response to Anticancer Drugs Clin. Cancer Res., June 15, 2005; 11(12): 4348 - 4356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Petit, D. J. Bearss, D. A. Troyer, R. M. Munoz, and J. J. Windle p53-independent Response to Cisplatin and Oxaliplatin in MMTV-ras Mouse Salivary Tumors Mol. Cancer Ther., February 1, 2003; 2(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rowley, P. Liu, and B. Van Ness Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan Blood, November 1, 2000; 96(9): 3175 - 3180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Pestell, S. M. Hobbs, J. C. Titley, L. R. Kelland, and M. I. Walton Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line Mol. Pharmacol., March 1, 2000; 57(3): 503 - 511. [Abstract] [Full Text]
|
|
|
|
|
|
F. Vikhanskaya, G. Colella, M. Valenti, S. Parodi, M. D'Incalci, and M. Broggini Cooperation between p53 and hMLH1 in a Human Colocarcinoma Cell Line in Response to DNA Damage Clin. Cancer Res., April 1, 1999; 5(4): 937 - 941. [Abstract] [Full Text] [PDF]
|
|